Latest Multiple myeloma Stories
TAMPA, Fla., Jan. 12, 2015 /PRNewswire/ -- Oxis International, Inc.
Funds Will Support Research into Treating Patients Who Have Received Chemotherapy For Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia NEW YORK, Dec.
This Approval Provides a New Treatment Option for a Patient Population With High Unmet Medical Need THOUSAND OAKS, Calif., Dec.
HERZLIYA, Israel, Dec.
Maximum tolerated dose (MTD) identified and expansion cohort open to enrollment; Minimal Response (MR) or better has been observed in 25% of 8 patients treated to date at the MTD or higher
- Note: This press release corresponds to abstract 31. SAN FRANCISCO, Dec. 6, 2014 /PRNewswire/ -- New IMBRUVICA(®) (ibrutinib) Phase II data announced here today by Pharmacyclics, Inc.
Data From Pivotal Trial Published in the New England Journal of Medicine and Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition THOUSAND OAKS, Calif.
SAN FRANCISCO, Dec.
Study shows the use of Internet-based tools can guide decision making in the treatment of multiple myeloma RESTON, Va., Dec.
Data from 13 accepted abstracts include: NORTH CHICAGO, Ill., Nov.